Brokerages slash Aurobindo Pharma's target price but remain bullish

Aurobindo Pharma vice-chairman and managing director K Nithyananda Reddy said the company had performed relatively better in this quarter in spite of the challenging times for the industry.

"We continue to see volume growth in the complex generics segment and are also making significant progress in the complex development programmes, including biosimilars. Further, we are also on track for completing the PLI project as per the committed timelines," Reddy said.

Goldman Sachs cut its target price to Rs 710 from Rs 840 and also slashed its earnings per share estimates by 14-17 percent for FY23-24. However, the brokerage upgraded its rating on Aurobindo Pharma shares to "buy". According to Goldman Sachs, the company's slow and steady recovery and valuations provide comfort.

CLSA maintained its "buy" rating on the pharma company's stock on undemanding valuations and multiple research and developmental projects. However, it too cut the company's target price to Rs 700 from Rs 800 per share.

The brokerage firm said that price erosion remains high for the base business, however, new launches, especially in injectable space, should offset price erosion. R&D pipeline of high-entry-barrier products may deliver from FY24, CLSA added.

Credit Suisse too had an "outperform" call on Aurobindo Pharma's stock, however, the brokerage firm too cut its target price Rs 790 from Rs 855 per share.